Academic Department of Dermatology, University General Hospital of Larissa and Faculty of Medicine, School of Health Sciences, University of Thessaly, Thessaly, Greece.
Academic Department of Neurology, University General Hospital of Larissa, Faculty of Medicine, School of Health Sciences, University of Thessaly, Thessaly, Greece.
Front Immunol. 2021 Jul 21;12:699848. doi: 10.3389/fimmu.2021.699848. eCollection 2021.
Patients with psoriasis are frequently obese and experience anxiety or suffer from depressive disorders. The immunopathogenesis of psoriasis and indeed psoriatic arthritis is largely based on the pivotal role of IL-17/IL-23 axis, to an extent that currently monoclonal antibodies selectively inhibiting IL-17 or IL-23 are routinely used for the treatment of psoriatic diseases. Emerging data, demonstrating a decisive role for IL-17 and IL-17 producing cell subsets, such as Th17 in the induction and progression of obesity and depression has led authors to suggest that psoriatic disease, obesity and anxiety/depression may indeed be interconnected manifestation of a state of immunedysregulation, the linked being IL-17 and its related cells. We discuss this hypothetical link in depth taking into account the beneficial effects anti-IL17 and anti-IL-17 receptor inhibitors in treating psoriatic disease and the on-going debate as to whether these biologics may exert a direct or indirect effect in ameliorating concomitant obesity and depressive disorders, which are frequently noted in the same patient.
患有银屑病的患者通常肥胖，并伴有焦虑或抑郁障碍。银屑病乃至银屑病关节炎的免疫发病机制在很大程度上基于 IL-17/IL-23 轴的关键作用，以至于目前选择性抑制 IL-17 或 IL-23 的单克隆抗体已被常规用于治疗银屑病疾病。新出现的数据表明，IL-17 和产生 IL-17 的细胞亚群（如 Th17）在肥胖和抑郁的诱导和进展中具有决定性作用，这使得作者提出银屑病疾病、肥胖和焦虑/抑郁实际上可能是免疫失调状态的相互关联的表现，其中的联系是 IL-17 及其相关细胞。我们深入讨论了这种假设的联系，考虑到抗 IL-17 和抗 IL-17 受体抑制剂在治疗银屑病疾病方面的有益效果，以及关于这些生物制剂是否可能直接或间接改善常见于同一患者的肥胖和抑郁障碍的持续争论。
